AzTrials
AzTrials

Somatic Symptom Disorder (DSM-5)NCT07646509

An Ecological Momentary Intervention for the Reduction of Impairment in Somatic Symptom Disorder

A study testing Music listening and Cognitive reappraisal in people with Somatic Symptom Disorder (DSM-5) and Impairment, run by University of Vienna at 1 site in Austria.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Persistent somatic symptoms significantly impair the daily lives of individuals with Somatic Symptom Disorder (SSD). Negative psychological factors (NPFs), such as catastrophizing and negative affectivity, further compound this impairment. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Music listening and Cognitive reappraisal
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteAustria
Study dates
26 Jun 2025to Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Somatic Symptom Disorder

Who cannot join

  • chronic physical illnesses that fully explain the somatic symptoms
  • current psychotic disorder
  • current bipolar disorder
  • current self-harming behavior
  • current suicidality
  • current psychotherapy
  • alcohol, drug, or medication dependence within the past 6 months

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Ricarda Nater-Mewes, Prof. contact

+43 463 2700 1604

ricarda.nater-mewes@univie.ac.at

Urs M. Nater, Prof. contact

+43-1-4277-47220

urs.nater@univie.ac.at

Austria1 site, 1 recruiting
  • University of Vienna

    Vienna, State of Vienna, 1010

    Ricarda Nater-Mewes, Prof., +43 463 2700 1604, ricarda.nater-mewes@univie.ac.at

    Nadja Plumbaum, MSc.

    Recruiting

Other trials in Austria

About this study

Persistent somatic symptoms significantly impair the daily lives of individuals with Somatic Symptom Disorder (SSD). Negative psychological factors (NPFs), such as catastrophizing and negative affectivity, further compound this impairment. Yet, few studies have examined strategies in daily life that directly target somatic symptoms and their dynamic relationship with NPFs. The goal of this clinical trial is to investigate if an Ecological Momentary Intervention (EMI) using music listening and cognitive reappraisal can reduce the intensity of and impairment due to somatic symptoms in 40 individuals with Somatic Symptom Disorder (SSD), aged 18-65 years.

Participants will report symptom intensity, impairment, and NPFs up to four times daily via a smartphone app over a six-week period. Using an intraindividual randomized controlled design, during weeks two to five, participants will be randomly assigned in the ratio of 50:25:25 to no intervention, music listening, and cognitive reappraisal, both at fixed times (evening measurement) and during episodes of acute somatic impairment.

Read the detailed description

Somatic symptoms, particularly when medically unexplained, are common stress-related health issues that significantly affect the daily lives of those experiencing them, especially in the more severe form known as Somatic Symptom Disorder (SSD). Specific negative psychological factors (NPFs), such as catastrophizing, negative affectivity, and rumination about somatic symptoms, may contribute to the intensity of and impairment caused by somatic symptoms (Mewes et al., 2022). The intensity and impairment associated with somatic symptoms are crucial outcome variables for both clinicians and those affected, and should therefore be considered in intervention studies (Rief et al., 2017). The best psychological treatment for somatic symptoms is cognitive behavioral therapy with low to moderate effect sizes (van Dessel et al., 2014). Considering the long waiting time for a therapy appointment and the small effect size, other interventions should be considered. Ecological Momentary Interventions (EMIs; Heron \& Smyth, 2010; Mewes, 2022) provide a promising approach for delivering interventions in real time, directly in people's daily lives and their natural environment. By collecting real-time data, EMIs can provide insights into the dynamic relationship between NPFs and somatic symptoms that would otherwise go unnoticed. Because they can address specific events as they occur, EMIs also enable just-in-time interventions in daily life. In addition, real-time assessment of treatment outcomes can contribute to the evaluation of effective interventions. Music listening could be such an intervention. Music listening plays an important role in pain management (Frei \& Szucs, 2025) as listening to music in accordance with the individual music preference has an analgesic effect on pain (Van der Valk Bouman et al., 2024). Music that is perceived as happy predicts the reduction of intensity and impairment caused by somatic symptoms in people with SSD (Feneberg et al., 2021). Thus, music listening seems to be a promising low-threshold intervention in daily life. Another promising approach to reduce somatic symptoms is cognitive reappraisal, since people with SSD show significantly less use of cognitive reappraisal than healthy individuals (Schnabel et al., 2022). When cognitive reappraisal is used as a standalone intervention, it reduces symptom annoyance in individuals with medically unexplained somatic symptoms (Kleinstäuber et al., 2019). Furthermore, when combined with other Cognitive Behavioral Therapy interventions such as stress management, it leads to an improvement in the impairment caused by somatic symptoms (Allen et al., 2006; Visser \& Bouman, 2001). The present study will examine the effects of an EMI in individuals with SSD, employing an intraindividual randomized controlled design with repeated measures. The investigators hypothesize that, from baseline (week 1) to post-intervention (week 6), participants will show a reduction in the weekly average intensity of somatic symptoms, a reduction in impairment due to somatic symptoms, and a reduction in the strength of negative psychological factors (intermediate effect). Furthermore, the investigators hypothesize that, following an acute event, impairment due to somatic symptoms, the intensity of somatic symptoms, and the severity of negative psychological factors will decrease more during an intervention event than during a control event (immediate effects). In addition, the investigators expect a decrease in somatic symptom severity as measured by the Patient Health Questionnaire-15, a decrease in symptom-related distress as measured by the Somatic Symptom Disorder - B Criteria Scale, and a change in perceived stress as measured by the Perceived Stress Scale -10 from pre-intervention (before week 1) to post-intervention (after week 6). Finally, the investigators hypothesize that higher expectations regarding future somatic symptom intensity will be associated with higher somatic symptom intensity at the subsequent assessment, and that higher expectations regarding future somatic symptom impairment will be associated with higher somatic symptom intensity at the subsequent assessment (fixed measurement points throughout the day). Potential participants will be recruited through flyers, online announcements, and potentially newspaper advertisements. The participants will be German-speaking individuals with SSD. Participants will be screened for SSD using a semi-structured interview based on the DSM-5, an operationalization used in a previous study (Mewes et al., 2022). The sample size was calculated using G*Power (Faul et al., 2007) for an F-test in a repeated-measures ANOVA with the within factors. The main outcome is a change in somatic symptoms, with an estimated effect size of f = 0.35 based on Kleinstäuber (2011), and an assumed correlation among repeated measures of 0.3. With a desired power of 0.90, an alpha error of 0.05, one group, two measurement points (average impairment levels baseline vs. post-intervention), and a nonsphericity correction of 1, the required total sample size was 33 participants. To ensure robustness and improve generalizability, and considering a dropout rate of 20%, the aim is to include 40 participants. Potential study participants will either undergo an initial online screening, during which they will be informed about the study and then contacted by us via phone, or proceed directly to a phone screening. During this call, information about the study will be provided, and a semi-structured interview to check for SSD will be conducted (Mewes et al., 2022). Upon receiving verbal consent to participate in the study, an appointment for the distribution of study materials will be arranged. If participants give their verbal consent during the phone screening, they can complete questionnaires, including potential control variables, before the distribution appointment. A link to the pre-questionnaire on SoSci Survey (Leiner, 2024) will be sent via email. If consent is not given during the phone screening, these questionnaires will be completed at the distribution appointment after consent is obtained. At the distribution appointment, the study information will first be discussed with the participants, and written consent to participate in the study will be obtained. Additionally, study materials (either a study smartphone or the installation of an app on the participants' smartphones) and a study manual will be distributed. The EMI begins one day after material distribution. After the post phase of the EMI, participants will again complete questionnaires on SoSci Survey (Leiner, 2024) regarding somatic symptoms. A return date for the materials will be scheduled via email. At the return appointment after the study period, all study materials will be collected. To achieve the research objective, an intraindividual randomized controlled trial will be conducted. An EMI will be conducted, which will be administered using the software MovisensXS. The study consists of three phases spanning a total of 42 days: The baseline phase (7 days), the intervention phase (28 days), and the post phase (7 days). During all three phases, data will be collected three times a day (11 am, 4 pm, and a self-initiated evening assessment). Additionally, in the intervention phase, an additional measurement point occurs 20 minutes after the evening assessment. During all three phases, participants receive prompts through the app at 11 am and 4 pm. The evening assessment can be initiated before going to bed by pressing a button in the app; participants will also receive a reminder at 9 pm. Additionally, participants will be asked to make self-initiated event-based inputs by pressing a button in the app whenever they feel acute somatic symptoms. They will then receive event-related questions immediately and 20 minutes later via a prompt. During the intervention phase, participants will be randomly assigned each day to either an intervention event or a control event. The intervention takes place in the evening and after self-initiated measurements, which are carried out due to impairment caused by somatic symptoms. On any given day, participants will have a 50% chance of receiving no intervention, and a 25% chance of receiving either music listening (Intervention 1) or cognitive reappraisal (Intervention 2). On days allocated to the intervention event, after the evening measurement, participants will engage in a fixed exercise session and receive another prompt 20 minutes after. In the control event, there will be no exercise between the measurement time points. In addition, at the event-based measurements, participants will again be randomly assigned in a 50:25:25 ratio to either continue with their current activity (control condition), engage in music listening (Intervention 1), or perform a cognitive reappraisal task of their somatic symptoms (Intervention 2).

Being tested
Music listening, Cognitive reappraisal, No intervention
Keywords
Ecological Momentary Intervention, Persistent Somatic Symptoms, Daily Life, Music, Cognitive reappraisal, Somatic Symptom disorder
Medical subject headings
Medically Unexplained Symptoms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Music listeningBehavioural

    Participants listen to self-selected happy music based on Feneberg et al. (2021). The duration is 10 minutes.

  • Cognitive reappraisalBehavioural

    Participants will be asked to write down their thoughts regarding their somatic complaints. They will be asked to consider the complaints from a more positive perspective. Subsequently, participants reread their written complaints. To develop another point of view, participants will be encouraged to apply more helpful thoughts to their somatic symptoms, such as "I feel really bad right now, but I'm certain I do not have a serious illness." (Kleinstäuber et al., 2019) The intervention lasts between 5 - 10 minutes.

  • No interventionBehavioural

    Participants continue with their previous task, but without music listening

Study groups in NCT07646509
Study groupRoleWhat they receive
Music listening/Cognitive reappraisal vs. no interventionExperimentalIntervention (music listening, cognitive reappraisal) vs. no intervention Every participant will be randomly assigned (25:25:50) to one of the following conditions after they feel more impaired by their somatic symptoms than usual or after the evening measurement: 1. Music listening: listening to self-selected music perceived as happy for 10 minutes (intervention condition) 2. Cognitive reappraisal: (intervention condition) 3. No intervention. Participants continue with their previous task, but without music listening (control condition).
Receives: Behavioral: Music listening; Behavioral: Cognitive reappraisal; Behavioral: No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in intermediate Intensity of and impairment by somatic symptoms and in the strength of negative psychological factors

    Intensity of somatic symptoms: visual analog scale (0-100; higher scores indicate a greater level of intensity), impairment by somatic symptoms visual analog scale (0-100; higher scores indicate a greater level of impairment), negative psychological factors: 5-point Likert scale; higher levels indicate stronger negative psychological factors.

    Measured: baseline (week 1) to post (week 6)

  2. Change in short-term impairment due to somatic symptoms

    Impairment due to somatic symptoms (visual analog scale, 0-100, higher scores indicate greater impairment).

    Measured: T0: directly after an event of acute impairment due to somatic symptoms; T1: 20 minutes after T0

  3. Change in short-term intensity of somatic symptoms

    Intensity due to somatic symptoms (visual analog scale, 0-100; higher scores indicate greater intensity)

    Measured: T0: directly after an event of acute impairment due to somatic symptoms; T1: 20 minutes after T0

  4. Change in short-term severity of negative psychological factors

    Negative psychological factors (5-point Likert scale).

    Measured: T0: directly after an event of acute impairment due to somatic symptoms. T1: 20 minutes after T0

Secondary outcomes (5)
  1. Change in somatic symptom severity measured with the Patient Health Questionnaire-15

    Somatic Symptom Severity (Patient Health Questionnaire-15): Values range from 0-30; Higher scores indicate a greater somatic symptom severity.

    Measured: pre (before week 1) to post (after week 6)

  2. Change in symptom-related distress measured with the Somatic Symptom Disorder-B Criteria Scale

    Symptom-related distress: Somatic Symptom Disorder-B Criteria Scale. The values range from 0 to 48. Higher scores indicate more symptom-related distress.

    Measured: Pre (before week 1) -Post (after week 6)

  3. Change in perceived stress measured with the Perceived Stress Scale 10

    Perceived stress (Perceived Stress Scale 10). The value ranges from 0 to 40; Higher scores indicate more perceived stress.

    Measured: pre (before week 1) - post (after week 6)

  4. Change of expectations regarding intensity of somatic symptoms

    Expectations regarding future somatic symptom intensity (visual analog scale; 0-100)

    Measured: fixed measurement points morning - day - evening

  5. Change of expectations regarding impairment due to somatic symptoms

    Expectations regarding future somatic symptom impairment: visual analog scale (0-100)

    Measured: fixed measurement time points morning - day - evening

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jun 2026
  2. Study start26 Jun 2025
  3. Primary completionOct 2026 (estimated)
  4. Study completionOct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Intra-Individually randomized design: Participants will be randomly assigned (25:25:50) to either one of the intervention condition (music, cognitive reappraisal) or the control condition
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07646509
Sponsor's protocol ID
SoMI
Status last verified
Jun 2026
First submitted
21 May 2026
Last updated
12 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.

    PubMed 11556941
  • Kleinstauber M, Witthoft M, Hiller W. Efficacy of short-term psychotherapy for multiple medically unexplained physical symptoms: a meta-analysis. Clin Psychol Rev. 2011 Feb;31(1):146-60. doi: 10.1016/j.cpr.2010.09.001. Epub 2010 Sep 16.

    PubMed 20920834
  • Abler B, Kessler H. Emotion Regulation Questionnaire - Eine deutschsprachige Fassung des ERQ von Gross und John. Diagnostica 2009;55(3):144-52. https://doi.org/10.1026/0012-1924.55.3.144

  • Gross JJ, John OP. Individual differences in two emotion regulation processes: implications for affect, relationships, and well-being. J Pers Soc Psychol. 2003 Aug;85(2):348-62. doi: 10.1037/0022-3514.85.2.348.

    PubMed 12916575
  • Barsky AJ, Wyshak G, Klerman GL. The somatosensory amplification scale and its relationship to hypochondriasis. J Psychiatr Res. 1990;24(4):323-34. doi: 10.1016/0022-3956(90)90004-a.

    PubMed 2090830
  • Van der Valk Bouman ES, Becker AS, Schaap J, Berghman M, Oude Groeniger J, Van Groeningen M, Vandenberg F, Geensen R, Jeekel J, Klimek M. The impact of different music genres on pain tolerance: emphasizing the significance of individual music genre preferences. Sci Rep. 2024 Sep 18;14(1):21798. doi: 10.1038/s41598-024-72882-2.

    PubMed 39294266
  • Frei, T., & Szucs, T. (2025). Effectiveness of music interventions on chronic pain: A systematic review. Journal of Psychiatry and Psychiatric Disorders, 9, 62-81.

  • Allen LA, Woolfolk RL, Escobar JI, Gara MA, Hamer RM. Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. Arch Intern Med. 2006 Jul 24;166(14):1512-8. doi: 10.1001/archinte.166.14.1512.

    PubMed 16864762
  • van Dessel N, den Boeft M, van der Wouden JC, Kleinstauber M, Leone SS, Terluin B, Numans ME, van der Horst HE, van Marwijk H. Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database Syst Rev. 2014 Nov 1;2014(11):CD011142. doi: 10.1002/14651858.CD011142.pub2.

    PubMed 25362239
  • Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.

    PubMed 17695343
  • Heron KE, Smyth JM. Ecological momentary interventions: incorporating mobile technology into psychosocial and health behaviour treatments. Br J Health Psychol. 2010 Feb;15(Pt 1):1-39. doi: 10.1348/135910709X466063. Epub 2009 Jul 28.

    PubMed 19646331
  • Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.

    PubMed 2748771
  • Visser S, Bouman TK. The treatment of hypochondriasis: exposure plus response prevention vs cognitive therapy. Behav Res Ther. 2001 Apr;39(4):423-42. doi: 10.1016/s0005-7967(00)00022-x.

    PubMed 11280341
  • Schnabel K, Petzke TM, Witthoft M. The emotion regulation process in somatic symptom disorders and related conditions - A systematic narrative review. Clin Psychol Rev. 2022 Nov;97:102196. doi: 10.1016/j.cpr.2022.102196. Epub 2022 Aug 21.

    PubMed 36063620
  • Mewes R. Recent developments on psychological factors in medically unexplained symptoms and somatoform disorders. Front Public Health. 2022 Nov 4;10:1033203. doi: 10.3389/fpubh.2022.1033203. eCollection 2022.

    PubMed 36408051

Questions about this trial

What is this clinical trial studying?

A study testing Music listening and Cognitive reappraisal in people with Somatic Symptom Disorder (DSM-5) and Impairment, run by University of Vienna at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ricarda Nater-Mewes, Prof. (+43 463 2700 1604, ricarda.nater-mewes@univie.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in intermediate Intensity of and impairment by somatic symptoms and in the strength of negative psychological factors (time frame: baseline (week 1) to post (week 6)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07646509, which also lists 33 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in